In accordance with our results, ticagrelor demonstrated a distinct therapeutic potential by modulating the NLRP3 inflammasome in the progression of diabetic cardiomyopathy in mice (Chen et al. 2020). The gene discussed is NLRP3; the disease is diabetic cardiomyopathy.